BioMarin appoints Mark J. Alles to Board of Directors, effective Jan 1, 2022

BIOMARIN PHARMACEUTICAL INC

Board size increased from ten to eleven members; Alles appointed to Board and Audit Committee.
Appointment effective January 1, 2022; conditions satisfied December 10, 2021.
Alles to receive standard independent director compensation and pro rata RSU grant ($400,000 annual value).
No arrangement or understanding with any person for the appointment; no related party transactions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark J. Alles

Director

BMRN · BIOMARIN PHARMACEUTICAL INC

Effective: 2022-01-01
Filed: December 15, 2021, 6:59 PM ET

appointed Mark J. Alles to the Board and to the Audit Committee of the Board, to be effective January 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark J. Alles was appointed as Director at BIOMARIN PHARMACEUTICAL INC.

Action: appointed
Role: Director

Exact text from the filing

appointed Mark J. Alles to the Board and to the Audit Committee of the Board, to be effective January 1, 2022.

View on SEC.gov

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001193125-21-357968

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.